KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Operating Leases (2019 - 2025)

Fulgent Genetics' Operating Leases history spans 6 years, with the latest figure at $3.6 million for Q3 2025.

  • For Q3 2025, Operating Leases changed N/A year-over-year to $3.6 million; the TTM value through Sep 2025 reached $3.6 million, changed N/A, while the annual FY2024 figure was $4.1 million, 42.35% down from the prior year.
  • Operating Leases for Q3 2025 was $3.6 million at Fulgent Genetics, down from $3.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $8.8 million in Q4 2022 and bottomed at $3.6 million in Q3 2025.
  • The 4-year median for Operating Leases is $6.6 million (2024), against an average of $5.9 million.
  • The largest annual shift saw Operating Leases dropped 18.74% in 2023 before it tumbled 47.38% in 2025.
  • A 4-year view of Operating Leases shows it stood at $8.8 million in 2022, then decreased by 18.74% to $7.1 million in 2023, then crashed by 42.35% to $4.1 million in 2024, then fell by 12.09% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Operating Leases are $3.6 million (Q3 2025), $3.8 million (Q2 2025), and $4.1 million (Q4 2024).